Background Glioma-induced immune dysregulation of the hematopoietic system has been
described in a limited number of studies. In this study, our group further demonstrates that …

Background Glioma-induced immune dysregulation of the hematopoietic system has been
described in a limited number of studies. In this study, our group further demonstrates that …

BACKGROUND Glioma-induced immune disfunction has been described in a limited
number of studies, and here we further demonstrate that gliomas also interrupt the cellular …

Despite its growing use in cancer treatment, immunotherapy has been virtually ineffective in
clinical trials for gliomas. The inherently cold tumor immune microenvironment (TIME) in …

Brain tumors are typically immunosuppressive and refractory to immunotherapies for
reasons that remain poorly understood. The unbiased profiling of immune cell types in the …

During brain neoplasia, malignant cells subjugate the immune system to provide an
environment that favors tumor growth. These mechanisms capitalize on tumor-promoting …

Glioblastoma multiforme (GBM) is an aggressive brain tumor for which current
immunotherapy approaches have been unsuccessful. Here, we explore the mechanisms …

Background Gliomas are recalcitrant tumors of the central nervous system. The tumor
immune microenvironment (TIME) in gliomas is considered immunosuppressive and making …

Immunotherapy has emerged as a promising approach to treat cancer, however, its efficacy
in highly malignant brain-tumors, glioblastomas (GBM), is limited. Here, we generate distinct …

Gliomas are one of the leading causes of cancer-related death in the adolescent and young
adult (AYA) population. Two-thirds of AYA glioma patients are affected by low-grade gliomas …